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EDITORIALS
Clinical Significance of Hepatitis B Virus Genotypes
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Traditionally, hepatitis B virus (HBV) is classifiedinto 4 subtypes or serotypes (adr, adw, ayr, andayw) based on antigenic determinants of the hep-
atitis B surface antigen.1 These subtypes can be further
classified into 9 serotypes (ayw1, ayw2, ayw3, ayw4, ayr,
adw2, adw4, adrq, and adrq).2 Epidemiologic studies
found that the prevalence of these serotypes varies in dif-
ferent parts of the world. In addition, antibody to the
common determinant, “a,” confers protection against all
serotypes. To date, there has been very little data on the
clinical significance of HBV serotypes.
Advances in molecular biology techniques revealed sig-
nificant diversities in sequences of HBV isolates, account-
ing for the allelic differences among the 4 major HBV
serotypes. Based on an intergroup divergence of 8% or
more in the complete nucleotide sequence, HBV can be
classified into 7 genotypes A-G.3-5 However, genotyping
can be accomplished based on a partial sequence of the
HBV genome such as the pre-S or S gene. Several meth-
ods have been used for HBV genotyping including direct
sequencing, restriction fragment length polymorphism,
line probe assay, and enzyme-linked immunoassay.
Contrary to hepatitis C virus genotyping, HBV geno-
typing is a research tool that is only beginning to gain
popularity among researchers in hepatitis B. Whether
HBV genotyping will constitute part of the clinical eval-
uation of hepatitis B patients depends on the availability
of simple and inexpensive tests and the relevance of the
information gained. Currently, restriction fragment
length polymorphism is the most commonly used
method for HBV genotyping. A line probe assay similar to
that used for hepatitis C virus genotyping is also available.
These assays can be easily applied in clinical diagnostic
laboratories. The key issue is, does knowledge of the HBV
genotype help in patient management? The specific ques-
tions include, (1) Is there a correlation between HBV
genotype and HBV replication, activity of liver disease,
clinical outcome, and treatment response? (2) What is the
predominant HBV genotype in each country? Is the geo-
graphical distribution of HBV genotypes related to the
endemicity of HBV infection? (3) Is there a correlation
between HBV genotype and risk of progression to chronic
infection? (4) Does infection with one HBV genotype
confer protection against infection with other HBV ge-
notypes?
Answers to some of the questions raised are beginning
to emerge but many of the answers are based on a few
studies in selected patient populations. Current informa-
tion on the geographical distribution of HBV genotypes is
summarized in Table 1. However, existing information is
incomplete. As an example, earlier studies suggested that
HBV genotype A is predominant in the United States. A
recent study indicated that HBV genotype G is also prev-
alent because it was present in 11 of 82 patients from the
state of Georgia.5 However, in an ongoing study involv-
ing 17 liver centers across the United States, we found all
7 HBV genotypes: A (33%), B (21%), C (34%), D (9%),
E (1%), F (1%), and G (1%) (personal observations).
HBV genotype A was more common among whites and
African Americans, whereas genotypes B and C were pre-
dominantly found in Asian Americans.
The high prevalence of HBV genotypes B and C
among Asians raise the possibility that HBV genotype
may be related to the endemicity of HBV infection. To
date, there has been no study on the relationship between
HBV genotype and mode of transmission. One study in
Switzerland found that genotype A was more common
among patients with chronic hepatitis B, whereas geno-
type D was more prevalent among patients with resolving
acute hepatitis B suggesting that HBV genotype A was
associated with a higher rate of chronic HBV infection.6
However, this study involved a total of 65 patients only
and confounding factors such as age at infection, gender,
mode of transmission, and coinfection with other hepati-
tis virus or human immunodeficiency virus were not an-
alyzed.
HBV genotypes may contribute to the wide range in
prevalence of HBV infection in different parts of the
world through differences in rates of replication and abil-
ities to evade immune clearance, but studies comparing
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the replication capacity and immune response of the var-
ious HBV genotypes have not been performed. However,
many studies have shown a strong relationship between
HBV genotypes and mutations in the precore and core
promoter regions that abolish or diminish the production
of hepatitis B e antigen (HBeAg).7-10 Thus, the most com-
mon precore mutation, a G to A substitution at nucleo-
tide 1896 (G1896A), which creates a premature stop codon
(eW28X) is found in association with HBV genotypes B,
C, and D but not genotype A. This accounts for the
preponderance of HBeAg-negative chronic hepatitis B in
Southern Europe and Asia. The basis for the genotype-
dependent selection of the precore G1896A mutation is
related to the need to maintain base pairing of the stem-
loop structure of the pregenome encapsidation sequence
().11,12 HBV genotypes B, C, and D frequently have a T
at nucleotide 1858, which is directly opposite nucleotide
1896 in the stem of , whereas HBV genotype A usually
has a C at nucleotide 1858, which forms a more stable
bond with the wild type (G) rather than the variant se-
quence (A).13
In the last issue of HEPATOLOGY, Kato et al. explored
the mechanism by which HBV genotype G, which has 2
stop codons in the precore region, maintains HBeAg pro-
duction.14 They found that all 4 patients with HBV ge-
notype G, who were HBeAg positive, were also coinfected
with HBV genotype A. In one patient who seroconverted
from HBeAg to hepatitis B e antibody, a shift from pre-
dominant HBV genotype A to predominant HBV geno-
type G was shown. Based on partial sequencing of a few
clones, the investigators suggested that there is evidence of
recombination between the two genotypes, but more
studies are needed to confirm these findings. It would also
be important to determine if patients infected with one
HBV genotype can be superinfected with other genotypes
and if infection with multiple HBV genotypes results in
more severe liver disease.
Several studies reported a correlation between HBV
genotype and HBeAg clearance. These studies, all of
Asian patients, found that the prevalence of HBeAg was
higher in patients with genotype C compared to those
with genotype B suggesting that HBeAg clearance oc-
curred at higher rates among patients with genotype
B.8,10,15 One study of 466 Japanese patients found that
HBeAg was present in 53% of genotype C versus 16% of
genotype B patients.10 This difference was maintained
after matching for gender, age, and liver disease in the two
groups. In a recent study of 269 Chinese patients, we
found that spontaneous HBeAg seroconversion occurred
approximately one decade earlier among patients with
HBV genotype B.16 We also showed that patients with
genotype B were more likely to have a sustained biochem-
ical remission after spontaneous HBeAg seroconversion.
A correlation between HBV genotype and liver disease
has also been found in several studies from Asia. One
study in Japan found that liver dysfunction (defined as
abnormal aminotransferase levels) was observed less fre-
quently in hepatitis B carriers with adw serotype (mainly
genotype B) compared to those with adr serotype (mainly
genotype C).17 Another study found that hepatitis B sur-
face antigen carriers with genotype B had lower histologic
activity scores.8 Two other studies involving a total of 490
Chinese patients with chronic HBV infection found that
genotype C was more prevalent in patients with cirrho-
sis.15,18 It is possible that a longer duration of high levels of
HBV replication may contribute to more active liver dis-
ease and, in turn, a higher rate of progression to cirrhosis
among patients with HBV genotype C. The relationship
between HBV genotypes and hepatocellular carcinoma is
inconclusive. One study found that HBV genotype B is
associated with development of hepatocellular carcinoma
at an earlier age,18 but this finding was not confirmed by
other studies.15,19,20 The relationship between HBV ge-
notypes and liver disease in other ethnic populations has
not been examined.
HBV genotype has also been related to response to
interferon therapy. One study of 64 German patients
found that the rate of interferon-induced HBeAg sero-
conversion was higher among patients with genotype A
than in those with genotype D (37% vs. 6%).21 Another
report involving 58 patients in Taiwan found that the rate
of HBeAg loss was significantly higher in patients with
genotype B compared to those with genotype C (41% vs.
15%).22 A third study in 35 HBeAg-negative patients
found that patients infected with HBV genotype A re-
sponded better than those with genotype D/E (70% vs.
40%).23 The correlation between HBV genotype and re-
sponse to other antiviral therapy (such as lamivudine)
remains to be determined. One study based on 26 pa-
tients reported that patients with adw serotype were more
likely to develop resistance to lamivudine than those with
Table 1. Geographic Distribution of HBV Genotypes and
Serotypes
Genotypes Serotypes Distribution
A adw2, ayw1 NW Europe, N America, Central Africa
B adw2, ayw1 SE Asia, China, Japan
C ayr, adrq, adrq,
adw2
SE Asia, China, Japan
D ayw2, ayw3 S Europe, Middle East, India
E ayw4 Africa
F adw4q American natives, Polynesia, Central and
South America
G adw2 United States, France
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ayw serotype but the correlation between serotype and
response was not mentioned.24
In summary, there is growing evidence that HBV ge-
notypes may influence HBeAg seroconversion rates, mu-
tational patterns in the precore and core promoter
regions, and the severity of liver disease. In addition, dif-
ferent HBV genotypes predominate in various parts of the
world. Thus, the heterogeneity in disease manifestations
and response to antiviral treatment among patients with
chronic hepatitis B in different parts of the world may, at
least in part, be attributed to differences in HBV geno-
types. Further studies are needed to confirm these obser-
vations to determine if HBV genotyping should be
included in the clinical evaluation of patients with
chronic HBV infection and if treatment should be tai-
lored accordingly.
CHI-JEN CHU, M.D.
ANNA S. F. LOK, M.D.
Division of Gastroenterology
University of Michigan Medical Center
Ann Arbor, MI
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